Next-Generation Imaging
Next-Generation Imaging
Zachary BessetteNext-Generation Imaging | September 13, 2023
Results of the BOP trial have shown 64Cu SAR-Bombesin can detect lesions in BCR prostate cancer that is PSMA PET-negative.
Read More
Zachary BessettemCRPC | September 6, 2023
SNMMI convened an autonomous workgroup to review prospective phase 2/3 clinical trials that used 177Lu-PSMA-617.
Emily MenendezNext-Generation Imaging | August 28, 2023
The SOLAR trial aimed to evaluate the safety and biodistribution of Copper Cu 64 PSMA I&T to detect prostate cancer.
Emily MenendezNext-Generation Imaging | August 2, 2023
18F-DCFPyL imaging has impacted clinical decision-making of treatment management for patients with prostate cancer.
Akhil Abraham Saji, MDNext-Generation Imaging | July 31, 2023
PSMA PET imaging is a leap forward in the fight to cure prostate cancer, especially as theranostic capabilities expand.
Emily MenendezSNMMI 2023 | June 29, 2023
Patients treated with enzalutamide prior to Lu-PSMA therapy had higher mean SUV values before treatment with 18 F-DCFPyL.
Emily MenendezSNMMI 2023 | June 29, 2023
68Ga-PSMA-11 and FDG-PET/CT scans were compared with scans from the VISION trial to assess patient eligibility for Pluvicto.
Emily MenendezSNMMI 2023 | June 29, 2023
The care management plans for several patients were changed after those patients underwent PSMA PET/CT.
Emily MenendezSNMMI 2023 | June 27, 2023
A research team developed a study to implement aPROMISE for the evaluation of PSMA and FDG-PET/CT scans acquired before RLT.
Emily MenendezSNMMI 2023 | June 25, 2023
The proposed method of algorithm-based TTV produced comparable TTV and whole-body SUVmean levels.
Zachary BessetteSNMMI 2023 | June 25, 2023
Researchers compared the performance of Ga-68 PSMA PET/CT vs F-18-NaF PET/CT in detecting bone metastases in prostate cancer.
Emily MenendezSNMMI 2023 | June 25, 2023
An encoder-decoder network employing 3-dimensional convolutions was trained to segment regions that were suspected of cancer.
Jérémie Calais, MD, MScASCO 2023 | June 4, 2023
Drs. Calais, Wallis discuss a post-hoc that showed PSMA PET as effective for treating pelvic, extrapelvic recurrent PC.
Emily MenendezASCO 2023 | June 3, 2023
The combination treatment of dual-PSMA targeting with mAb and SML is feasible, and a follow-up study is in progress.
Zachary BessetteASCO 2023 | June 2, 2023
64Cu-SAR-bisPSMA may be safe and effective for detecting PSMA-expressing lesions, and 200MBq may be the optimal dose.
Emily MenendezNext-Generation Imaging | May 30, 2023
POSLUMA is a diagnostic imaging agent for the PET detection of PSMA-positive lesions in patients with prostate cancer.
Emily MenendezNext-Generation Imaging | May 11, 2023
A newly developed prognostic risk score had a good model fit for predicting OS in internal and external validation cohorts.
Emily MenendezAUA 2023 | April 28, 2023
When testing interaction with the use of MDT, patients with positive PSMA PET not receiving MDT had a higher risk of CR.
Leah LawrenceProstate Cancer | April 19, 2023
Several physicians highlight the newest data on radiation for metastatic prostate cancer and its role moving forward.
Cora N. Sternberg, MDnmCRPC | April 11, 2023
Dr. Sternberg shares the therapeutic options for nmCRPC patients, how stage at diagnosis impacts these options, and more.